Jan 6 | News
CHADDS FORD, Pa. (AP) — Endo Pharmaceuticals Inc. said today it has agreed to pay up to $180 million for licensing rights to market a potential pain treatment from BioDelivery Sciences International Inc. that would be delivered through a dissolvable film applied to the inside of the cheek.
|
Dec 12 2011 | News
Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Opana ER designed to be crush-resistant.
|
Nov 2 2011 | News
Endo Pharmaceuticals today announced that the FDA has approved Felodipine Extended-release tablets USP, 2.5mg, 5mg and 10mg. Qualitest Pharmaceuticals, the generic business unit of Endo Pharmaceuticals, will manufacture and distribute the Felodipine Extended-release tablets.
|
Oct 31 2011 | News
Endo Pharmaceuticals today announced that it will relocate its corporate headquarters to a new facility based in Malvern, Pa., by December 2012.
|
Aug 23 2011 | Video
Endo Pharmaceuticals' Robert Cobuzzi speaks about the challenges emerging biopharmaceutical companies face.
|
Aug 18 2011 | News
CHADDS FORD, Pa. (AP) — Endo Pharmaceuticals Holdings Inc.
said Wednesday that it is ending a partnership on an experimental back pain
drug.
|
Jun 27 2011 | News
CHADDS FORD, Pa. (AP) — Endo Pharmaceuticals Holdings Inc.
said Friday that it has recalled two lots of the painkiller Endocet, after some
bottles were found to contain tablets that had a higher dosage of acetaminophen
than was indicated on the label.
|
May 5 2011 | News
Mylan’s subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone
and Aspirin Tablets USP, 4.8355 mg/325 mg, based on an agreement with licensing
partner Coastal Pharmaceuticals.
|
Apr 11 2011 | News
NEW YORK
(AP) — Endo Pharmaceuticals Holdings Inc. said yoday it is buying urology and
pelvic health company American Medical Systems Inc. for about $2.6 billion.
|
Jan 28 2011 | News
Endo Pharmaceuticals announced today that it has entered
into a collaboration agreement with European-based Orion Corporation for the
discovery, development and commercialization of assets in Oncology.
|